Better Therapeutics- Tradeable Rights - March 2021 OverviewTrack Better Therapeutics- Tradeable Rights - March 2021's operating income ($-30M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2023
Trailing 12 months ending Sep 30, 2023
The latest operating income for MCADR is $-30M as of September 2023. That compares with $-42M in the prior-year period — up 29.6% year over year. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.
Over the past year, MCADR's operating income moved from $-42M to $-30M — a 29.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.
A operating income figure of $-30M for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting MCADR's operating income ($-30M), review year-over-year change from $-42M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
